ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarker
Birna Þorvaldsdóttir(Karolinska Institutet), Richard Rosenquist(Karolinska University Hospital), Julio Delgado(Departament de Salut), Fanny Baran‐Marszak(Sorbonne Université), Florence Nguyen‐Khac(Inserm), Davide Rossi(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Fátima Mirás(Hospital Universitario 12 De Octubre), Mattias Mattsson(Uppsala University Hospital), Inmaculada Rapado(Wellcome Sanger Institute), Riccardo Moia(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Stamatia Laidou(Centre for Research and Technology Hellas), Christian Brieghel(Copenhagen University Hospital), Elı́as Campo(Hospital Clínic de Barcelona), Lydia Scarfò(IRCCS Ospedale San Raffaele), Joaquín Martínez‐López(Hospital Universitario 12 De Octubre), Jesús María Hernández‐Rivas(Universidad de Salamanca), Gian Matteo Rigolin, Silvia Bonfiglio(Vita-Salute San Raffaele University), Panagiotis Baliakas(Uppsala University), María José Larráyoz(Navarre Institute of Health Research), Lars Bullinger(Stanford University), Manja Meggendorfer(Université Paris-Sud), Gianluca Gaïdano(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Κώστας Σταματόπουλος(Centre for Research and Technology Hellas), Jonathan C. Strefford(University of Southampton), Bárbara Tazón‐Vega(Broad Institute), María Hernández‐Sánchez(Universidad de Salamanca), Zadie Davis(Royal Bournemouth Hospital), Larry Mansouri(Uppsala University), Francesc Bosch(Vall d'Hebron Hospital Universitari), Ferran Nadeu(Centro de Investigación Biomédica en Red de Cáncer), Blanca Espinet(Hospital Del Mar), Carsten Utoft Niemann(University of Copenhagen), Helen Parker(University of Southampton), María José Terol(Hospital Clínico Universitario de Valencia), Jana Kotašková(Central European Institute of Technology), Šárka Pospı́šilová(Central European Institute of Technology), Anna Puiggros(Hospital Del Mar), Rocío Benito(Universidad de Salamanca), Javier de la Serna(Hospital Universitario 12 De Octubre), Paolo Ghia(Vita-Salute San Raffaele University), Lesley‐Ann Sutton(Karolinska Institutet), Karin E. Smedby(Karolinska Institutet), Marı́a José Calasanz(Navarre Institute of Health Research), David Oscier(Royal Bournemouth Hospital), Thorsten Zenz(Universität Ulm), Antonio Cuneo(University of Ferrara), Ana E. Rodríguez‐Vicente(Universidad de Salamanca)
Cited by 5
Related Papers
Genomic Classification and Prognosis in Acute Myeloid Leukemia
|New England Journal of Medicine|2016|4.4k
The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma
|New England Journal of Medicine|2002|3.9k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications
|Blood|2011|2k
Stromal Gene Signatures in Large-B-Cell Lymphomas
|New England Journal of Medicine|2008|1.8k